These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 36465312)

  • 1. Cannabis use and opioid relapse: An exploratory survival analysis of prospectively collected data.
    Naji L; Rosic T; Sanger N; Dennis B; Hillmer A; Hudson J; Worster A; Paul J; Marsh DC; Thabane L; Samaan Z
    Front Psychiatry; 2022; 13():1046649. PubMed ID: 36465312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
    Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
    JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder.
    Nosyk B; Min JE; Homayra F; Kurz M; Guerra-Alejos BC; Yan R; Piske M; Seaman SR; Bach P; Greenland S; Karim ME; Siebert U; Bruneau J; Gustafson P; Kampman K; Korthuis PT; Loughin T; McCandless LC; Platt RW; Schnepel KT; Socías ME
    JAMA; 2024 Dec; 332(21):1822-1831. PubMed ID: 39418046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States.
    Parish WJ; Mark TL; Zarkin GA; Weber E
    Addiction; 2022 Jan; 117(1):141-150. PubMed ID: 34033177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naloxone provision to emergency department patients recognized as high-risk for opioid use disorder.
    Lane BH; Lyons MS; Stolz U; Ancona RM; Ryan RJ; Freiermuth CE
    Am J Emerg Med; 2021 Feb; 40():173-176. PubMed ID: 33243535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L; Iversen J; Wand H; Maher L
    Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
    Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
    Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.
    Park TW; Larochelle MR; Saitz R; Wang N; Bernson D; Walley AY
    Addiction; 2020 May; 115(5):924-932. PubMed ID: 31916306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early buprenorphine-naloxone initiation for opioid use disorder reduces opioid overdose, emergency room visits, and healthcare cost compared to late initiation.
    Sun T; Aroke H; Kogut S; Katenka N; Bratberg J; Buchanan A
    Am J Drug Alcohol Abuse; 2022 Mar; 48(2):217-225. PubMed ID: 34780312
    [No Abstract]   [Full Text] [Related]  

  • 11. The association between cannabis use and outcome in pharmacological treatment for opioid use disorder.
    Rosic T; Kapoor R; Panesar B; Naji L; Chai DB; Sanger N; Marsh DC; Worster A; Thabane L; Samaan Z
    Harm Reduct J; 2021 Feb; 18(1):24. PubMed ID: 33622351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in opioid use disorder and overdose among opioid-naive individuals receiving an opioid prescription in Massachusetts from 2011 to 2014.
    Burke LG; Zhou X; Boyle KL; Orav EJ; Bernson D; Hood ME; Land T; Bharel M; Frakt AB
    Addiction; 2020 Mar; 115(3):493-504. PubMed ID: 31691390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of naloxone education for patients receiving buprenorphine-containing prescriptions indicated for opioid use disorder at an independent community pharmacy.
    Hines KL; Garofoli GK; Garofoli MP; Elswick BM; Winstanley EL
    J Am Pharm Assoc (2003); 2020; 60(6):e205-e214. PubMed ID: 32800678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Evidence for Cannabis' Role in Opioid Use Disorder.
    Wiese B; Wilson-Poe AR
    Cannabis Cannabinoid Res; 2018; 3(1):179-189. PubMed ID: 30221197
    [No Abstract]   [Full Text] [Related]  

  • 15. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
    Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prenatal Buprenorphine/Naloxone or Methadone Use on Neonatal Outcomes in Michigan.
    Goshgarian G; Jawad R; O'Brien L; Muterspaugh R; Zikos D; Ezhuthachan S; Newman C; Hsu CD; Bailey B; Ragina N
    Cureus; 2022 Aug; 14(8):e27790. PubMed ID: 36106254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
    Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
    Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline Factors Associated with Mortality in Patients Who Engaged in Buprenorphine Treatment for Opioid Use Disorder: a Cohort Study.
    Fine DR; Yu L; Triant VA; Baggett TP; Metlay JP
    J Gen Intern Med; 2020 Aug; 35(8):2375-2382. PubMed ID: 32206993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States.
    Sun T; Katenka N; Kogut S; Bratberg J; Rich J; Buchanan A
    Pharmacoepidemiology; 2022 Dec; 1(3):101-112. PubMed ID: 36743423
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.